Medical/Pharmaceuticals
Cambrex to Expand Stability Storage Business with New Facility in Durham, North Carolina
EAST RUTHERFORD, N.J., July 8, 2024 /PRNewswire/ -- Cambrex today announced the expansion of its stability storage business, Q1 Scientific, which offers environmentally-controlled stability storage services to the pharmaceutical, medical device, and life sciences industries. Q1 Scientific will op...
2024-07-08 18:00
2723
DP Technology Announces Nomination of Development Candidate, a CNS Penetrable Lp-PLA2 Inhibitor for Alzheimer's Disease
BEIJING, July 8, 2024 /PRNewswire/ -- DP Technology, an "AI for Science" paradigm-driven company, today announced the nomination of DPT0416, a novel CNS penetrable small molecule targeting Lp-PLA2, as a preclinical candidate for the treatment of Alzheimer's disease (AD). AD is the most frequent ...
2024-07-08 17:23
2236
DP Technology Announces Nomination of Development Candidate, a Potential Best-in-Class Lp-PLA2 Inhibitor for DR and DME
* The nomination of novel Lp-PLA2 inhibitor DPT0415 for the treatment of DR & DME. * DPT0415 is a highly potent, selective and safe Lp-PLA2 inhibitor with sufficient target engagement at a dose of 0.3 mpk and robust efficacy in the STZ-induced rat DR model. * This project further validates ...
2024-07-08 17:00
2379
Immorna Biotherapeutics Receives U.S. FDA IND Clearance to Conduct Phase 1/2 Study of JCXH-211 IV as Monotherapy and in Combination with Checkpoint Inhibitor in Patients with Advanced Solid Tumors
MORRISVILLE, NC., July 8, 2024 /PRNewswire/ -- Immorna Biotherapeutics, Inc. (Immorna), a clinical stage biotechnology company developing both self-replicating and conventional mRNA-based therapeutics and vaccines, announced today that the U.S. Food and Drug Administration (FDA) has cleared its ...
2024-07-08 16:28
2238
Sirnaomics Announces Interim Results for Successful Completion of the Second Cohort of Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Therapeutics
HONG KONG and GERMANTOWN, Md. and SUZHOU, China, July 8, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or " Sirnaomics"; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, to...
2024-07-08 14:30
3467
Parents: Discover the Three Essential Pillars of Childcare for Your Child's Optimal Development
JAKARTA, Indonesia, July 2, 2024 /PRNewswire/ -- Morinaga Milk is unveiling the three key pillars of childcare under its latest campaign: Potential-Attention-Nutrition. As a leading brand under Kalbe Nutritionals, Morinaga is launching this campaign to help 21st century parents meet the challeng...
2024-07-08 14:13
2397
BioCity announces its endothelin receptor A selective antagonist SC0062 met the primary endpoint in IgA nephropathy in 2-SUCCEED trial: a randomized, double-blind, placebo-controlled Phase 2 trial
SHANGHAI, July 8, 2024 /PRNewswire/ -- BioCity Biopharma (BioCity) announced its endothelin receptor type A (ETA) selective antagonist SC0062 met the primary endpoint of proteinuria reduction in the 2-SUCCEED trial: a randomized, double-blind, placebo-controlled, dose-ranging phase 2 clinical tri...
2024-07-08 13:41
2385
Olverembatinib Approved for Commercialization in Macau China
ROCKVILLE, Md. and SUZHOU, China, July 8, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies for hematological malignancies, announced today that its novel BCR-ABL1 tyro...
2024-07-08 08:55
3472
Innovent Launches Environmental, Social and Governance (ESG) Website to Advance Sustainability and Corporate Responsibility
SAN FRANCISCO and SUZHOU, China, July 8, 2024 /PRNewswire/ -- Environmental, Social and Governance (ESG) criteria are key indicators of a company's long-term sustainability. Innovent Biologics has been actively addressing the United Nations' Sustainable Development Goals (SDGs) and recently launc...
2024-07-08 08:00
3139
ESHRE 40th Annual Meeting: Air pollution linked to a decrease in IVF birth rate success, new study shows
AMSTERDAM, July 8, 2024 /PRNewswire/ -- A pioneering study, presented today at the ESHRE 40th Annual Meeting in Amsterdam, has revealed that exposure to fine particulate matter (PM) prior to the retrieval of oocytes during in vitro fertilisation (IVF) can reduce the odds of achieving a live birth...
2024-07-08 06:01
2810
FAIR PLAY MENARINI INTERNATIONAL AWARD, A MAGICAL NIGHT AT FIESOLE FOR THE GRAND FINALE
FLORENCE, Italy, July 5, 2024 /PRNewswire/ -- A finale to remember: the sporting legends delighted the packed terraces of the Roman Theatre in Fiesole, bringing the curtain down on the28th Fair Play Menarini International Award. Yesterday, the event dedicated to the values of ethics, loyalty, and...
2024-07-05 21:48
4212
XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country
- Following its initial approval for the treatment of relapsed/refractory multiple myeloma (R/R MM), XPOVIO® has now received approval as a monotherapy for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) marking the second approved indication of ...
2024-07-05 21:18
7992
Hinova Pharmaceuticals receives FDA Fast Track Designation for HP518 for Treatment of AR+ Triple-Negative Breast Cancer (TNBC)
CHENGDU, China, July 5, 2024 /PRNewswire/ -- Hinova Pharmaceuticals Inc. (688302.SH), a leading biopharmaceutical company dedicated to developing innovative cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for HP518, an investi...
2024-07-05 21:00
5380
LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition
GAITHERSBURG, Md., July 5, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for in...
2024-07-05 19:00
5803
IASO Bio and Innovent Enhance Strategic Collaboration in Cell Therapy
SHANGHAI and NANJING, China and SAN JOSE, Calif., July 5, 2024 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing, and marketing innovative cell therapies and antibody products, and Innovent Biologics, Inc. ("Innovent", H...
2024-07-05 16:30
4927
Innovent and IASO Bio Enhance Strategic Collaboration in Cell Therapy
SAN FRANCISCO and SUZHOU, China, July 5, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic,...
2024-07-05 16:30
6104
Biostar Pharma Announces FDA Clearance of the IND Application for a Phase 2 Study of Utidelone Injection (UTD1) in HER2- Breast Cancer Brain Metastasis
SAN FRANCISCO, July 5, 2024 /PRNewswire/ -- Biostar Pharma, Inc., the U.S. subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. (Biostar), which is a synthetic biology-driven biopharma company focusing on the development and commercialization of innovative oncology drugs, announced today that ...
2024-07-05 16:07
2531
Zhejiang Doer Biologics Completes Enrollment of the Phase 1b/2a Trial Evaluating DR10624 in Obese Subjects with Modest Hypertriglyceridemia
HANGZHOU, China, July 5, 2024 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that the company has completed the enrollment in the Phase1b/2a trial ...
2024-07-05 15:56
4129
Neurosurgeon Dr. Teo Kejia Shares Advancements in Brain Surgery Techniques for Optimal Patient Care
SINGAPORE, July 4, 2024 /PRNewswire/ -- Conventional brain surgery involves an invasive method of removing part of the skull to access the brain for treatments. It is used to treat various conditions, including brain tumours, aneurysms, epilepsy, and traumatic brain injuries. While this type of s...
2024-07-04 15:28
3672
LOTTE BIOLOGICS Holds Groundbreaking for Songdo Bio Campus
* Plans to Join the Ranks of the TOP 10 Global CDMOs, Heralding a New Era in the Global CDMO Landscape SEOUL, South Korea, July 3, 2024 /PRNewswire/ -- In a landmark event signaling its ambitious foray into the biopharmaceutical sector, LOTTE BIOLOGICS, under the leadership of CEORichard W. Lee...
2024-07-04 11:17
4572
Week's Top Stories
Most Reposted
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 328 media titles]
2026-02-19 14:30
Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 326 media titles]
2026-02-24 12:00
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00
Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 301 media titles]
2026-02-24 16:13
Vitafoods Asia 2026 Expands by 30%: A Bigger, More Dynamic Trade Event with Exciting New Features & Increased International Participation
[Picked up by 288 media titles]
2026-02-23 10:09
Most Read
/C O R R E C T I O N -- Republic Power Group Limited (NASDAQ: RPGL)/
2026-02-20 06:36
8500